Regulatory Affairs

Aimovig®

Summary of the Local Safety Risk Management Plan

Active substance(s) (INN or common name):	*Erenumab*
Product(s) concerned (brand name(s)):	*Aimovig*
Document status:	*Final*
Version number of the RMP Public Summary:	*2.0 from RMP v. 3.1*
Date of final sign off of the RMP Public Summary	*23-July-2021*

Template version 1.0 Feb 2021

Table of contents

Summary of the risk management plan for Aimovig (Erenumab)

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of Aimovig is a concise document and does not claim to be exhaustive.

As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of Aimovig in Switzerland is the "Arzneimittelinformation/ Information sur le médicament" (see www.swissmedic.ch) approved and authorized by Swissmedic. Novartis Pharma Schweiz AG is fully responsible for the accuracy and correctness of the content of the published summary RMP of Aimovig.

I. The medicine and what it is used for

Aimovig is authorized for the prophylaxis of migraine in adults who have at least 4 migraine days per month (see SmPC for the full indication). It contains erenumab (a human IgG2 monoclonal antibody) as the active substance and it is given by sc injections. Further information about the evaluation of Aimovig's benefits can be found in Aimovig's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage:
http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/004447/human_med_002275.jsp

II. Risks associated with the medicine and activities to minimize or further characterize the risks

Important risks of Aimovig, together with measures to minimize such risks and the proposed studies for learning more about Aimovig's risks, are outlined below in Table 13-2. Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorized pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

If important information that may affect the safe use of Aimovig is not yet available, it is listed under 'missing information' below.

II.A: List of important risks and missing information

Important risks of Aimovig are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Aimovig. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established for Aimovig yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 1 List of important risks and missing information

List of important risks and missing information	
Important identified risks	None
Important potential risks	Cardiovascular outcomes in patients with pre-existing myocardial infraction, cerebrovascular accident, transient ischemic attack, angina unstable and poorly controlled hypertension
Missing information	Use in pregnant women (including those at risk of pre-eclapsia)

II B: Summary of important risks

Table 2 Important potential risk: Cardiovascular outcomes in patients with pre-existing myocardial infarction, cerebrovascular accident, transient ischemic attack, angina unstable and poorly controlled hypertension

Evidence for linking therisk to the medicine	A comprehensive assessment of CV safety in over 2500 patients in the erenumab clinical Phase II/III program including cardiovascular, cerebrovascular and peripheral vascular AEs, BP assessments and electrocardiograms. The program employed an external, independent Cardiovascular Events Committee to adjudicate the selected CV, cerebrovascular, and peripheral vascular AEs. While patients with recent (i.e., within the last 12 months) cardiovascular events such as MI, stroke, TIA, unstable angina, coronary artery bypass surgery or other revascularization procedures were excluded, patients with risk factors for cardiovascular disease (e.g., diabetes, hypertension, and hyperlipidemia) were allowed to participate. Over 70% of subjects had 1 or more baseline cardiovascular risk factor(s) while approximately 30% of subjects had 2 or more. The

	summation of this evaluation demonstrated no evidence of a relationship between erenumab and cardiovascular, cerebrovascular, and peripheral vascular events in both individual andaggregate AEs. In the subjects with 2 or more CV risk factors at baseline, the incidence of AEs was slightly higher than in subjects with0 or 1 CV risk factor at the baseline, but similar to the placebo and across treatment groups. No relevant differences were observed between these subgroups inthe most frequent AEs or AEs associated with cardiac disorders. Looking at the effect on BP, there was no clinically meaningful difference in either systolic or diastolic BP or in the frequency of increased blood pressure AEs with erenumab versus placebo. A few patients reached a post-baseline systolic BP > 160mmHg and these patients were already hypertensive or pre-hypertensive (defined as systolic BP ≥ 140mmHg or diastolic BP ≥ 90mmHg) at baseline and had medical history of hypertension or other confounding factors. There were no relevant differences in change in CV medication observed between erenumab and placebo.
Risk factors and riskgroups	Since this is a potential risk, no attributable increase to erenumab has been established. Therefore, by definition, no risk groups or risk factors can be identified.
Risk minimization measures	Routine risk minimization measures- SmPC Section 5.1 (Pharmacodynamic properties) SmPC Section 4.4 (Special warnings and precautions for use)
Additional pharmacovigilance activities	Additional risk minimization measures – None NIS - A Non-Interventional Study (CAMG334A2023) to examine patient characteristics and drug utilization patterns in migraine patientstreated with prophylactic drugs in the Nordic registries.

Table 3 Missing information: Use in pregnant woman (including those at risk of pre-eclampsia)

Risk minimization measures	Routine risk minimization measures- SmPC Section 4.6 (Fertility,pregnancy and lactation) Routine pharmacovigilance activities beyond ADRs reporting andsignal detection - Intensive monitoring of pregnancy outcomes
Additional pharmacovigilance activities	Additional risk minimization measures – None NIS - A Non-Interventional Study (CAMG334A2023) to examine patient characteristics and drug utilization patterns in migraine patientstreated with prophylactic drugs in the Nordic registries

II C: Post-authorization development plan

II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorization or specific obligation of Aimovig.

II.C.2. Other studies in post-authorization development plan

Table 4 Other studies in the post-authorization development plan

Study short name	Rationale and study objectives
NIS (Non-Interventional Study; CAMG334A2023)	There is a theoretical concern that inhibition of CGRP effect may result in lack of compensatory vasodilation, particularly in the context of the coronary circulation during ischemia-related diseases/conditions. The precise extent of the role played by the canonical CGRP receptor in mediating vasodilatory mechanisms remains unknown as CGRP binds to several other receptors, such asthe amylin 1 receptor to which it binds with similar potency as amylin and erenumab selectively binds to the CGRP receptor. Furthermore, multiple pathways and mediators are involved in vasodilation (e.g. nitric oxide, substance P, neurokinins), and it is therefore not exactly clear, what effects, if any, there may be from inhibiting the CGRP pathway alone. In addition, CGRP among other factors plays an important role in maintaining normal fetoplacental development, fetal survival, and vascular adaptations during pregnancy. Hence, there is a theoretical

	concern that inhibition of CGRP effects could have adverse effects onfetoplacental development for pregnant women. This NIS will characterize the population treated with erenumab in theNordic countries. This datatogether with the evaluation of CV adverseevents from ongoing studies combined with AEs from the post- marketing setting will provide information on the appropriateness of conducting further post-marketing studies to assess the CV safety in patients treated with erenumab in the real-world setting. The NIS aimsto estimate: • Number of migraine patients prescribed with a migraine prophylactic drug (with and without CV history) • Number of pregnant migraine patients prescribed with erenumab and other prophylactic treatments • Pattern of erenumab and possible comparator utilization (prescriber, pattern of use, length of treatment, switching) • General characteristics and clinical features of migraine patients prescribed prophylactic drug • As exploratory: rates of CV events